Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 15;22(22):12312.
doi: 10.3390/ijms222212312.

Incretins in the Therapy of Diabetic Kidney Disease

Agnieszka Przezak  1 , Weronika Bielka  1 , Andrzej Pawlik  1
Affiliations
Review

Incretins in the Therapy of Diabetic Kidney Disease

Agnieszka Przezak et al. Int J Mol Sci. .

Abstract

Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality. Incretins are peptide hormones derived from the gastrointestinal tract, that besides causing enhancement of insulin secretion after oral glucose intake, participate in many other metabolic processes. Antidiabetic drug classes, such as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide receptor agonists, which way of action is based on incretins facility, not only show glucose-lowering properties but also have nephroprotective functions. The aim of this article is to present the latest information about incretin-based therapy and its influence on diabetic kidney disease appearance and progression, point its potential mechanisms of kidney protection and focus on future therapeutic possibilities bound with these two antidiabetic drug classes.

Keywords: diabetes; diabetic kidney disease; incretins; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The influence of GLP1 on different tissues.
Figure 2
Figure 2
The metabolism of GLP1. A description is given in the text above.
Figure 3
Figure 3
The pathophysiology of diabetic kidney disease. A description is given in the text above.
See this image and copyright information in PMC

References

    1. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986;63:492–498. doi: 10.1210/jcem-63-2-492. - DOI - PubMed
    1. Vilsbøll T., Holst J.J. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004;47:357–366. doi: 10.1007/s00125-004-1342-6. - DOI - PubMed
    1. Kahn S.E., Cooper M.E., Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet. 2014;383:1068–1083. doi: 10.1016/S0140-6736(13)62154-6. - DOI - PMC - PubMed
    1. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Investig. 1993;91:301–307. doi: 10.1172/JCI116186. - DOI - PMC - PubMed
    1. Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52. doi: 10.1007/BF02427280. - DOI - PubMed

MeSH terms